JPRN-UMIN000026043招募中2 期
Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidine - Phase 2 trial of TAS-102 with bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on standard therapies
Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery0 个研究点目标入组 28 人开始时间: 2017年2月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Previously received TAS-102 or regorafenib 2) Serious drug allergy (excluding oxaliplatin) 3) Serious myelosuppression 4) Active infectious disease 5) Interstitial lung disease or pulmonary fibrosis 6) Watery diarrhea 7) Serious comorbid illness (intestinal paralysis, obstruction, uncontrolled diabetes, renal failure, liver failure, etc) 8) Other active malignancies 9) Pregnancy, breast feeding, or women who desire to preserve fecundity. Men who want his partner to be pregnant 10) Patients who were judged inappropriate for the entry to this study by the investigators
研究者
相似试验
招募中
2 期
Switch Maintenance StudyColorectal cancerJPRN-jRCT1051180117emura Mamoru55
招募中
2 期
Phase II study of TAS-102 plus bevacizumab as maintenance therapy after induction chemotherapy with bevacizumab, oxaliplatin, and fluoropyrimidine in patients with metastatic colorectal cancerColorectal cancerJPRN-UMIN000031317Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group55
已完成
2 期
A phase II study of TAS-102 plus Bevacizumab therapy for advanced/recurrent colorectal cancer with difficulty on intensive chemotherapyColorectal CancerJPRN-UMIN000022705Osaka medical Center for Cancer and Cardiovascular Diseases20
尚未招募
2 期
TAS-102 plus Bevacizumab combination as first-line treatment in elderly patients with metastatic colorectal cancer, phase 2 trialmetastaic colorectal cancerJPRN-UMIN000020240Tokushima University Hospital30
已完成
2 期
Phase II trial of the addition of bevacizumab to alectinib beyond progressive disease in ALK-positive advanced non-small-cell lung cancer.ALK-positive non-small cell lung cancerJPRN-UMIN000017828iigata Lung Cancer Treatment Group11